Trials / Completed
CompletedNCT01268124
Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HTC-867 Administered Orally to Healthy Japanese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, randomized (a process that is used to decide whether you will take study drug or a placebo during the study), inpatient study which will assess the safety and tolerability of HTC-867 in healthy male Japanese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HTC-867 |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2010-12-29
- Last updated
- 2010-12-29
Source: ClinicalTrials.gov record NCT01268124. Inclusion in this directory is not an endorsement.